Effect of naringenin in Qianggu capsule on population pharmacokinetics in Chinese women with primary osteoporosis  by Jiannong, Wang et al.
TOPIC
JTCM |www. journaltcm. com April 15, 2015 |Volume 35 | Issue 2 |
Wang Jiannong, Institute of Basic Medical Sciences, Xi Yuan
Hospital, China Academy of Chinese Medical Sciences, Bei-
jing 100093, China
Jiang Junjie, Xie Yanming, Wei Xu, Li Jianpeng, Chinese
Clinical Basic Institute, China Academy of Chinese Medical
Sciences, Beijing 100700, China
Duan Jingli, Xiong Xin, Department of Pharmaceutics,
Third Hospital Affiliated Peking University, Beijing 100083,
China
Supported by Grant from Significant Drug Research and
Development in Important State Science and Technology
Specific And Key Technique Research (Key Issues Research
on Re-evaluation of Listed Herbal Hedicine, No.
2009ZX09502-030); Visiting Fellow Joint Innovation Re-
search Project of The China Academy of Chinese Medical Sci-
ences (Exploratory Research in Population Pharmacokinet-
ics of Bioactive Compounds of Osteopractic Total Flavone
Based on Total Quantum Statistical Moment. No. ZZ070834)
Correspondence to: Prof. Xie Yanming, Chinese Clinical
Basic Institute, China Academy of Chinese Medical Sciences,
Beijing 100700, China. Datamining5288@163.com
Telephone: +86-13911112416; +86-64014411-3302
Accepted: July 11, 2014
Abstract
OBJECTIVE: To characterize naringenin (NAR) pop-
ulation pharmacokinetics (PPK) in Chinese women
with primary osteoporosis.
METHODS: Ninety-eight female patients with pri-
mary osteoporosis from the Jingshan, Beixinqiao, Ji-
aodaokou, Chaoyangmen, and Donghuamen com-
munities in Beijing, China, aged 40 to 80 years, re-
ceived oral Qianggu capsules (250 mg). Blood sam-
ples were collected before and at 0.5, 1, 2, 3, 4, 6, 8,
10, 12, and 24 h after administration. The concentra-
tion of NAR in the blood samples was measured us-
ing high performance liquid chromatography-tan-
dem mass spectrometry. PPK analyses were per-
formed with nonlinear mixed-effect modeling soft-
ware (version 7.1.2, PsN3.2.12). The clearance (C1),
central distribution volume (V), absorption rate
constant (Ka1), peripheral distribution volume (VII),
and inter-compartmental clearance (CLII) were set
as parameters and estimated by the base model,
covariate model, and final model. Kidney-Yang defi-
ciency [Shenyangxu (SYAX)] and liver-kidney-Yin de-
ficiency (Ganshenyinxu) are patterns of symptoms
in Traditional Chinese Medicine that were set as co-
variates, along with age, height, blood urea nitro-
gen, serum creatinine, alanine transaminase, aspar-
tate transaminase, and hyperlipidemia. Both step-
wise forward and backward procedures were ac-
complished to build models. The final model was
evaluated by internal and external validation, visual
predictive check, bootstrap, and leverage analysis.
RESULTS: A one compartment open model with
first order degradation was the best fitted to the
concentration-time profiles following oral adminis-
tration of NAR. The mean of population parameters
of the final model, C1, SYAX on C1, V, Ka1, CLII, and
VII, were measured to be 37.6 L/h, 0.427 L, 123 L/h,
0.12/h, 0.3056, and 1.446, respectively. Inter-individ-
ual variability was estimated and SYAX was identi-
fied as a significant covariate.
CONCLUSION: The population pharmacokinetic
model described in this study could effectively
characterize the pharmacokinetic profile of NAR fol-
lowing administration of a single dose of oral
Qianggu capsules in Chinese women with primary
osteoporosis. Among the tested covariates, only SY-
AX was a significant factor.
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INTRODUCTION
Qianggu capsules, which we developed in 2003, have
been widely used in China for the treatment of women
with primary osteoporosis. Naringenin (4′ , 5, 7-trihy-
droxyflavanone, NAR), the active compound found in
Qianggu capsules, has been reported to increase the
bioavailability of other drugs, and have antioxidant,1 an-
ti-ulcer,2 anti-tumor, anti-allergy, phlegm removing,
cough suppressing, anti-inflammatory, and anti-hyper-
lipidemia activities.3
Various methods have been reported for quantification
of NAR in biological samples to support preclinical
and clinical studies. Most reported approaches involve
long and tedious sample detection and preparation,
such as solid phase extraction or protein precipitation,
which involves multiple steps.3-5 Further, there is limit-
ed plasma data or pharmacokinetic parameters of NAR
in humans. Inter-subject variability in pharmacokinet-
ics can also vary considerably among individual drugs
and depends on a variety of factors. One potential fac-
tor involves Traditional Chinese Medicine (TCM)
symptoms. We aimed to use HPLC-MS/MS assay
method to assess the sensitivity of NAR population
pharmacokinetics to TCM symptoms.
MATERIALS ANDMETHODS
The following diagnostic criteria, inclusion criteria, ex-
clusion criteria, exclusion criteria, subject recruitment,
drug administration and blood sampling, chemicals
and reagents, instrumentation, HPLC, analysis condi-
tions, and sample preparation methods are based on
previous reported methods with some minor modifica-
tions.6
Subject recruitment
Ninety-eight female subjects, aged 40 to 80 years, were
recruited from the communities of Jiangshan, Beixinq-
iao, Jiaodaokou, Chaoyangmen, and Donghuamen in
Beijing, China between September 2010 and April
2011. All subjects gave informed consent before partici-
pation, and the study was approved by Ethics Commit-
tee of Chinese Clinical Basic Institute, China Academy
of Chinese Medical Sciences (Approval number:
2010No13).
Diagnostic criteria
The diagnostic criteria for osteoporosis were mainly ob-
tained from Guideline of Clinical Diagnosis: Subvol-
ume of Osteoporosis and Bone Mineral Salt Diseases
(First edition).1 Subjects whose T-score was less than
or equal to﹣2.5 were considered to have osteopenia.3
Inclusion criteria
Patients were included if they volunteered to be a sub-
ject and signed an informed consent form. Those pa-
tients who were female, aged 40 to 80 years, and met
the diagnostic criteria for osteoporosis were included.
Exclusion criteria
Men were excluded from the study, as were women
who did not meet the diagnostic criteria for bone densi-
ty (T-score >﹣2.5).
Chemicals and reagents
Purified water was prepared by a Milli-Q water purifi-
cation system (Millipore, Shanghai, China). Acetoni-
trile, methanol, formic acid, and ethyl acetate were all
HPLC grade (American Fisher Chemicals Ltd.,
Waltham, MA, USA). Sodium acetate and ascorbic ac-
id were all analytical grade (Beijing Chemical Agent
Company, Beijing, China). β-glucuronidase was sup-
plied by Sigma Co. (St. Louis, MO, USA). Naringenin
standard (batch No. 10042231, naringenin content
was 98.0% ) was from Tong Tian Biotech Co., Ltd.,
(Shanghai, China), and hesperidin standard (batch No.
0721-9506, content hesperidin was 98.0%) was from
the National Institute for the Control of Pharmaceuti-
cal and Biological Products (Beijing, China).
Instrumentation
HPLC-MS/MS system (Agilent, Palo Alto, CA, USA)
was used in this study. The HPLC-MS/MS system was
comprised of a 6410 Triple Quadrapole mass spec-
trometer, and 1200 system was equipped with a 2170
binary system controller, a 1211 pump, a 1322-de-
gasser, a 1329A auto-sampler, and a 1316A column ov-
en. Data were collected and processed using Mass-
Hunter software B 01.03 (Agilent, Palo Alto, CA,
USA).
Drug administration and blood sampling
Blood samples of volunteers were taken after a single
oral dosage of Qianggu capsules (Beijing Qi Huang
Pharmaceutical Co., Ltd.). The principle drug in each
dose was 250 mg of total flavonoid of Drynaria fortu-
nei (Kunze) J. Sm., which contains 75mg of NAR. 2 mL
blood samples were collected from their median cubi-
tal vein and stored in 4 mL ethylene diamine tetraace-
tic acid microcentrifuge tubes immediately before and
0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after oral adminis-
tration. The samples were centrifuged at 10 000 ×g for
15 min at 4 ℃. A total of 500 μL of plasma were sepa-
rated and kept frozen at − 80 ℃ until analysis. Blank
plasma was purchased from the Red Cross Blood Cen-
ter Warehouse of China and kept at a temperature of
﹣40℃.
HPLC analysis conditions and sample preparation
An Agilent XDB C18 (50 mm × 4.6 mm, 1.8 μm) was
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used. The mobile phase was acidic water (containing
0.1% formic acid) (A) and acetonitrile (B) in the fol-
lowing gradient: 90% A→ 30% A (0-4 min), 100% B
(4.1 min), and 90% A (5.1 min) with a flow rate of
1.0 mL/min, separating ratio of 1:3, column oven tem-
perature of 35 ℃ , and total run time of 3.0 min for
each injection. The mass spectrometer was operated us-
ing electrospray ionization with an ionspray voltage of
+ 5500 V. Negative ion multiple-reaction-monitoring
mode analysis was performed using nitrogen as the col-
lision gas. The ionspray pressure was set at 40 psi, the
flow rate of drying gas at 11 L/min, the drying gas tem-
perature at 350 ℃, and precursor/product ion pairs for
NAR and hesperidin at m/z 579.2/271.1 and m/z
609.3/301.0, respectively. With r2 equal to 0.9928,
the linear relationship was statistically significant over
the concentration range between 0.5 and 200 ng/L.
The regression equation y = 0100089 + 41541x (y =
peak area of NAR, x = concentration of NAR in plas-
ma) was obtained by implementing the least-squares
method. The limit of quantification was 0.5 ng/L
based on a signal-to-noise ratio of 4∶1.
A 0.2 mL aliquot of each plasma sample was trans-
ferred to 1.5 mL polypropylene tubes with 40 μL of in-
ternal standard, vortexed for 30 s, and then vortexed
for another 2 min after 1 mL of ethyl acetate was add-
ed to the tube. After centrifugation (10 000 ×g), the su-
pernatant was combined and transferred to another
polypropylene tube and evaporated to dryness at room
temperature under nitrogen gas. The final residue was
dissolved in 100 μL of mobile phase, and the solution
was injected into an HPLC system.
Base model selection
All data collected were subsequently processed by non-
linear mixed-effect modeling (NONMEM) software
(NONMEM 7.1.2, PsN312112, CA, USA). Typical
values of pharmacokinetic parameters of NAR were es-
timated using first-order post-hoc estimation. Parame-
ters were assumed to follow the log-normal distribu-
tion across the population, and the residual error was
characterized by a combined proportional and additive
error model. All steps in the development of the phar-
macokinetics model were executed based on the likeli-
hood ratio test. An additional parameter was reserved if
the resultant decrease in the objective function value
(OFV) was > 3.84 (P < 0.05).
One compartment model with first-order absorption
and elimination was chosen, based on the known phar-
macokinetic properties of NAR. The basic model was
implemented in the subroutine ADVAN6 in NON-
MEM, and the structural parameters to be estimated
were clearance (C1), central distribution volume (V),
absorption rate constant (Ka1), peripheral distribution
volume (VII), and inter-compartmental clearance
(CLII) The model frame is shown in Figure 1.
In the first step of the analysis, differential equations of
the NAR base model were created as follows (equa-
tions 1-4):
(1)
(2)
(3)
(4)
These differential equations were then simplified based
on the following assumption:
(5)
The differential equations were therefore set up as fol-
lows (equations 6-8):
(6)
(7)
(8)
Univariate analysis
The relationship between the Bayesian estimates and
the main covariates were explored. Bodyweight, height,
age, aspartate transaminase (AST), alanine transami-
nase (ALT), blood urea nitrogen (BUN), serum creati-
nine (Scr), and the symptom patterns, kidney-yang de-
ficiency [Shenyangxu (SYAX)] and liver-kidney-yin de-
ficiency [Ganshenyinxu (GSYI)], were tested in the
univariate analysis. All covariates were tested one by
one. A decrease of ≥ 3.84 in the OFV compared with
the base model was selected as a statistically significant
(P < 0.05) improvement of the fit of the model to the
data.
Multiple regression analysis
Except for the weight of patients, TCM patterns were
considered to be a possible covariate, which was added
to the basic model using a forward selection procedure.
All of the statistically significant covariates in the uni-
variate analysis were entered into the full model. In the
backward detection method, they were removed one at
P.O.
Absorption ka NaringeninVc1
km
Glocoside
Vc2
kmo
Naringenin
(in vitro)
Figure 1 Frame of the base model
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a time. The values of individual parameters for each
subject from the basic model were plotted against these
two covariates and graphically inspected for their rela-
tionships. Additional population models were exam-
ined with the progressive introduction of any covari-
ates that were found to contribute to the statistically
significant drop in OFV. A recursive backward elimina-
tion procedure was then performed to further refine
the model, and a covariate was removed from the mod-
el if the increase of OFV was less than 10.84 (P <
0.001) during the exclusion. Two methods were ap-
plied for the creation of the full covariate model. In
these methods, both forward and backward methods
were used.
RESULTS
Baseline of subjects
Ninety-eight patients provided 253 data points for the
population pharmacokinetics analysis. The time distri-
bution scatter diagram is shown in Figure 2. Summary
demographic information of TCM patterns is provid-
ed in Table 1, and other demographic information
characteristics are shown in Figure 3.
The points indicate that most detectable blood samples
were collected between 0 min and 15 h. The y-axis in-
dicates the concentration of naringenin in ng/μL.
Diagnostics and validation of the NAR base model
The main diagnostic plots for the base model are sum-
marized in Figures 4 and 5, and the simulation results
are shown in Figure 7. Both the observed concentra-
tion data versus predicted concentration data of the
population and individuals were scattered around the
line of unity slope. Meanwhile, the weighted residuals
were uniformly spread around the zero line, and the
weighted residuals were normally distributed, which in-
dicate that there was no bias in the base model.
The results showed successful minimization, good cor-
relation, and no large standard errors. It was found
that one compartment base model with first-order ab-
sorption and elimination best fit the concentration-time
profiles of NAR following oral administration.
Creation of the NAR final model with forward
method one
The covariate model of NAR was created using two
methods. In method one, the forward method was con-
ducted. The decrease in OFV in the forward method
covariate model is shown in Table 2. Statistically sig-
nificant (P = 0.05) improvements of the fit of the
model to the data were found in SYAX on Cl
(ΔOFV = ﹣11.88), height on Cl (ΔOFV = ﹣5.797),
ALT on V (ΔOFV = ﹣4.881), atherosclerosis in Ka1
(ΔOFV = ﹣ 8.295), coronary heart disease on Ka1
(ΔOFV = ﹣7.032), hyperlipidemia on Ka1 (ΔOFV =
﹣4.813), and age on Ka1 (ΔOFV =﹣3.9).
Creation of the NAR final model with backward
method one
All of the statistically significant covariates during
univariate analysis were entered into the full model.
In the backward deletion step, only SYAX led to an
increase in OFV > 6.63 (P < 0.01). The control
stream of the backward analysis covariate model is
shown in Table 3.
Diagnostics of the NAR final model with method one
Figure 8 shows the main informal diagnostic plots for
the final model by basic goodness-of-fit plots of ob-
served concentrations versus population and individual-
ly predicted concentrations, weighted residuals versus
observed concentration, and weighted residuals versus
time.
Both the observed concentration data versus predicted
concentration data of population and individual were
scattered around the line of unity slope. The weighted
residuals were uniformly spread around the zero line,
and the weighted residuals fell into a normal distribu-
tion, which demonstrated that there was no bias in the
base model.
Covariate
HYPERL
ATHER
CHD
FT
HYPERT
GSYIX
PSYAX
SYAX
Cases
Negative
77
84
85
89
74
69
87
59
Positive
21
14
13
9
24
29
11
39
Notes: ATHER: atherosclerosis; CHD: coronary heart diseases;
FT: faint; GSYIX: Ganshenyinxu; HYPERL: hyperlipidemia;
HYPERT: hypertension; PSYAX: Pishenyangxu; SYAX:
Shenyangxu; TCM: Traditional Chinese Medicine.
Table 1 Demographic information of TCM andWestern medi-
cine syndromes
250
200
150
100
50
0
Co
nc
(ng
/m
L)
0 5 10 15 20 25
Time (h)
Figure 2 Time distribution scatter diagram of the blood sam-
ples
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Population parameters of the NAR final model with
method one
The population parameters estimates of the final mod-
el with method one are listed in Table 4.
Visual predictive checking of the NAR final model
with method one
To assess the final model, the final model was checked
by visual predictive checking, and the results are shown
in Figure 8.
To analyze the clinical impact of the statistically signifi-
cant covariates, concentration profiles were simulated
for a 250 mg single dose regimen. The results are
shown in Figure 9.
Creation of the NAR final model with forward
method two
The Covariate model of NAR was created using two
methods. In method two, forward method was con-
ducted. The decrease in OFV of the forward method
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Figure 3 Histogram of demographic information of included patients
A: age distribution; B: height distribution; C: BUN distribution; D: Scr distribution; E: ALT distribution; F: AST distribution. BUN:
blood urea nitrogen; Scr: serum creatinine; ALT: alanine transaminase; AST: aspartate transaminase.
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Figure 5 Summary of main diagnostic plots for the base
model
Black lines showed an almost normal distribution of the con-
ditional weighted residuals, which means that the main di-
agnostic plots for the base model were reliable.
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Figure 4 Main diagnostic plots for the base model
A: the blue lines represent every possible opposite blood concentration point of the observations, the red lines represent the real
average plots, and the black lines indicate the fitness; B: two different visual forms of the 95% confidence line (plot form and line
form); C: every blue point indicates a prediction of possible blood concentration, the red lines indicate the average of these blood
concentrations. Almost all points were around the average line, which means that the weighted residuals are almost the same; D:
conditional weight residuals were around the zero line; E-H: the blue lines indicate every possible opposite blood concentration
point of the observations, the red lines indicate the real average plots, and the black line indicates the fitness.
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Figure 6 Simulation results for the base model
Dotted lines represent the 95% confidence line, while the
solid line indicates the line simulator of the average blood
concentration of naringenin (NAR). The y-axis indicates
blood concentration of NAR in ng/µL.
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Figure 7 Observed data versus predicted data of the final model of method one
A: the blue lines represent every possible opposite blood concentration point of the observations, the red lines represent the real
average plots, and the black lines indicate the fitness; B: two different visual forms of the 95% confidence line (plot and line
forms); C: every blue point indicates a predication of possible blood concentration, and the red lines indicate the average of these
blood concentrations. Almost all the points were around the average line, which means that the weighted residuals are almost
the same; D: conditional weight residuals were around the zero line; E: the normal distribution of the conditional weighted residu-
als means that the main diagnostic plots for the base model were reliable.
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Control stream
401_naringenin.ctl
401SYAX vs cl.ctl
401ALT vs cl.ctl
401AST vs cl.ctl
401BUN vs cl.ctl
401Weight vs cl.ctl
401ATHER vs cl.ctl
401CHD vs cl.ctl
401FT vs cl.ctl
401GSYIX vs cl.ctl
401Height vs cl.ctl
401SCR vs cl.ctl
401HYPERL vs cl.ctl
401HYPERT vs cl.ctl
401PSYAX vs cl.ctl
401Age vs cl.ctl
401AST vs V.ctl
401ALT vs V.ctl
401BUN vs V.ctl
401Weight vs V.ctl
401ATHER vs V.ctl
401CHD vs V.ctl
401FT vsV.ctl
401GSYIX vs V.ctl
401Height vs V.ctl
401SCR vs V.ctl
401HYPERL vs V.ctl
401HYPERT vs V.ctl
401PSYAX vs V.ctl
401SYAX vs V.ctl
401Age vs V.ctl
401AST vs KA.ctl
401ALT vs KA.ctl
401BUN vs KA.ctl
401Weight vs KA.ctl
401ATHER vs KA.ctl
401CHD vs KA.ctl
401FT vs KA.ctl
401GSYIX vs KA.ctl
401Height vs KA.ctl
401SCR vs KA.ctl
401HYPERL vs KA
401HYPERT vs KA.ctl
401PSYAX vs KA.ctl
401SYAX vs KA
401Age vs KA.ctl
401SYAX vs cl.ctl
402ATHER vs KA.ctl
402Age vs KA.ctl
OFV
1200.5670
1188.6870
1199.2250
1199.9580
1200.7020
1199.7300
1199.9210
1199.6200
1200.5690
1200.5790
1194.7700
1200.7960
1200.2840
1198.7810
1200.5740
1200.7230
1199.7270
1195.6860
1200.5690
1197.1370
1200.6510
1200.5910
1199.4970
1200.5960
1198.3950
1200.3170
1200.5670
1200.1470
1200.5690
1199.2770
1200.7960
1200.6440
1200.6960
1199.5060
1200.8020
1192.2720
1193.5350
1200.5700
1199.4700
1200.6250
1200.9240
1195.7540
1199.6160
1200.5670
1198.7500
1196.6670
1188.6870
1178.6500
1182.3430
BASE MODEL
ATHER ON KA
AGE ON KA
Model description
BASE MODEL
SYAX ON CL
ALT ON CL
AST ON CL
BUN ON CL
WEIGHT ON CL
ATHER ON CL
CHD ON CL
FT ON CL
GSYIX ON CL
HEIGHT ON CL
SCR ON CL
HYPERL ON CL
HYPERT ON CL
PSYAX ON CL
AGE ON CL
AST ON V
ALT ON V
BUN ON V
WEIGHT ON V
ATHER ON V
CHD ON V
FT ON V
GSYIX ON V
HEIGHT ON V
SCE ON V
HYPERL ON V
HYPERT ON V
PSYAX ON V
SYAX ON V
AGE ON V
ASTO ON KA
ALT ON KA
BUN ON KA
WEIGHT ON KA
ATHER ON KA
CHD ON KA
FT ON KA
GSYIX ON KA
HEIGHT ON KA
SCR ON KA
HYPERL ON KA
HYPERT ON KA
PSYAX ON KA
SYAX ON KA
AGE ON KA
△OFV
-
﹣11.880
﹣1.342
﹣0.609
0.135
﹣0.837
﹣0.646
﹣0.947
0.002
0.012
﹣5.797
0.229
﹣0.283
﹣1.786
0.007
0.156
﹣0.840
﹣4.881
0.002
﹣3.430
0.084
0.024
﹣1.070
0.029
﹣2.172
﹣0.250
0.000
﹣0.420
0.002
﹣1.290
0.229
0.077
0.129
﹣1.061
0.235
﹣8.295
﹣7.032
0.003
﹣1.097
0.058
0.357
﹣4.813
﹣0.951
0.000
﹣1.817
﹣3.900
-
﹣10.037
﹣6.344
P < 0.05 (OFV > 3.84)
-
Y
N
N
N
N
N
N
N
N
Y
N
N
N
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
Y
Y
N
N
N
N
Y
N
N
N
Y
-
Y
Y
Table 2 Control stream and OFV values of the forward covariate model of method one
Notes: full model: 402 Age vs ka.ctl→ 402 full.ctl. When OFV > 3.84 then P < 0.05; N = no; Y = yes. ALT: alanine transaminase; AST:
aspartate transaminase; ATHER: atherosclerosis; BUN: blood urea nitrogen; C1: clearance; CL: inter-compartmental clearance; CHD: cor-
onary heart diseases; FT: faint; GSYIX: Ganshenyinxu; HYPERL: hyperlipidemia; HYPERT: hypertension; KA: absorption rate constant;
OFV: objective function value; PSYAX: Pishenyangxu; SCR: serum creatinine; SYAX: Shenyangxu; TCM: Traditional Chinese Medicine;
V: central distribution volume; and VII: peripheral distribution volume.
148
JTCM |www. journaltcm. com April 15, 2015 |Volume 35 | Issue 2 |
Wang JN et al. / Clinical Study
covariate model is shown in Table 5. Statistically signif-
icant (P < 0.05) improvements of the fit of the model
to the data were found in SYAX on Cl (ΔOFV =
﹣12.123) and height on Cl (ΔOFV =﹣7.615).
The control stream and the data file of method two are
501_naringenin.ctl and naringenin3-cn1.csv, respec-
tively. The control stream and the results are shown in
Table 5.
Creation of the NAR final model with backward
method two
All of the statistically significant covariates during
univariate analysis were entered into the full model.
In the backward deletion step, only SYAX led to an
increase in OFV > 6.63 (P < 0.01). The control
stream of the backward analysis covariate model is
listed in Table 6.
Diagnostics of the NAR final model with method two
The main informal diagnostic plots for the final model
by basic goodness-of-fit plots of observed concentra-
tions versus population and individually predicted con-
centrations, weighted residuals versus observed concen-
tration, and weighted residuals versus time are shown
in Figure 10.
Both the observed concentration data versus predicted
concentration data of population and individual were
scattered around the line of unity slope. The weighted
residuals were uniformly spread around the zero line,
and the weighted residuals fell into a normal distribu-
tion, which demonstrate that there was no bias in the
base model.
Population parameters of the NAR final model with
method two
The population parameters estimates of the final mod-
el with method two are listed in Table 7.
Parameters
OFV
Cl [(L/h)]
SYAX on Cl
V (L)
Ka [(L/h)]
CL IIV
V IIV
Ka IIV
Error model (addictive)
Base model
1200.567
24.500 (0.064)
-
222 (0.095)
0.209 (0.174)
0.068
0.195
1.490
0.678
Final model
1182.343
22.600 (0.114)
0.846 (0.287)
203 (0.310)
0.185 (0.047)
0.4494
0.196
1.407
0.665
Notes: C1: clearance; CL: inter-compartmental clearance; Ka:
absorption rate constant; OFV: objective function value; SYAX:
Shenyangxu (insufficiency of kidney-yang); V: central distribu-
tion volume; IIV: peripheral distribution.
Table 4 Population parameters estimates of the final model
with method one
Control stream
401SYAX vs cl.ctl
402FULL.AGE.ctl
402FULL.SYAX.ctl.
OFV
1182.3430
1188.6870
1196.6670
Model description
Full model
Remove age
Remove syax
△OFV
-
6.344
14.324
P < 0.01 (OFV > 6.63)
-
N
Y
Notes: final model: 402full.age.ctl→ 402final.ctl. When OFV > 3.84 then P < 0.05; OFV: objective function value; N = No; Y = Yes.
Table 3 Control stream and the OFV values of the backward covariate model
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Figure 8 Visual predictive checking of the final model with
method one
The top dotted line illustrated 95th percentile of average
concentration; the solid line represents the mean concentra-
tion. The low dotted line illustrates the 5th percentile of av-
erage concentration.
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Figure 9 Concentration-time profiles predicated in popula-
tion in the Chinese women with primary osteoporosis fol-
lowing a 250 mg once dosing regimen with method one
The red dotted line (top) illustrated SYAX 95th percentile.
The red solid line represented SYAX mean. The red dotted
line (low) illustrated SYAX 5th percentile. The blue dotted
line (top) illustrated No SYAX 95th percentile. The blue solid
line represented No SYAX mean. The blue dotted line (low) il-
lustrated No SYAX 5th percentile.
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Control stream
501_naringenin.ctl
501SYAX vs cl.ctl
501ALT vs cl.ctl.
501AST vs cl.ctl
501BUN vs cl.ctl
501Weight vs cl.ctl
501ATHER vs cl.ctl
501CHD vs cl.ctl
501FT vs cl.ctl
501GSYIX vs cl.ctl
501Height vs cl.ctl
501SCR vs cl.ctl
501HYPERL vs cl.ctl
501HYPERT vs cl.ctl
501PSYAX vs cl.ctl
501Age vs cl.ctl
501AST vsV.ctl
501ALT vsV.ctl
501BUN vsV.ctl
501Weight vsV.ctl
501ATHER vsV.ctl
501CHD vsV.ctl
501FT vsV.ctl
501GSYIX vsV.ctl
501Height vsV.ctl
501SCR vsV.ctl
501HYPERL vsV.ctl
501HYPERT vsV.ctl
501PSYAX vsV.ctl
501SYAX vsV.ctl
501Age vsV.ctl
501SYAX vs cl.ctl
502Height vs cl.ctl
﹣1324.7020
﹣1333.6100
OFV
﹣1312.5790
﹣1324.7020
﹣1313.1300
﹣1315.0760
﹣1312.4710
﹣1314.1350
﹣1312.6650
﹣1312.8960
﹣1312.5790
﹣1312.5440
﹣1320.1940
﹣1312.5550
﹣1313.8000
﹣1314.8980
﹣1312.5740
﹣1312.7580
﹣1312.6390
﹣1312.6840
﹣1312.5530
﹣1314.3920
﹣1312.5000
﹣1312.5530
﹣1312.7060
﹣1312.5650
﹣1313.0390
﹣1314.2050
﹣1312.5560
﹣1312.4950
﹣1312.5820
﹣1314.0450
﹣1311.7970
502SYAX.VX.CL
HEIGHT vs CL
Model description
BASE MODEL
SYAX ON CL
ALT ON CL
AST ON CL
BUN ON CL
WEIGHT ON CL
ATHER ON CL
CHD ON CL
FT ON CL
GSYIX ON CL
HEIGHT ON CL
SCR ON CL
HYPERL ON CL
HYPERT ON CL
PSYAX ON CL
AGE ON CL
AST ON V
ALT ON V
BUN ON V
WEIGHT ON V
ATHER ON V
CHD ON V
FT ON V
GSYIX ON V
HEIGHT ON V
SCE ON V
HYPERL ON V
HYPERT ON V
PSYAX ON V
SYAX ON V
AGE ON V
△OFV
-
﹣12.123
﹣0.551
﹣2.497
0.108
﹣1.556
﹣0.086
﹣0.317
0
0.035
﹣7.615
0.024
﹣1.221
﹣2.319
0.005
﹣0.179
﹣0.006
﹣0.105
0.026
﹣1.813
0.079
0.026
﹣0.127
0.014
﹣0.46
﹣1.626
0.023
0.084
﹣0.003
﹣1.466
0.782
-
﹣8.908
P < 0.05 (OFV > 3.84)
-
Y
N
N
N
N
N
N
N
N
Y
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
-
Y
Notes: final model: 502SYAX vs cl.ctl→ 502full.ctl. When OFV > 3.84 then P < 0.05; Y = yes; N = no. ALT: alanine transaminase; AST:
aspartate transaminase; ATHER: atherosclerosis; BUN: blood urea nitrogen; C1: clearance; CL: inter-compartmental clearance; CHD: cor-
onary heart diseases; FT: faint; GSYIX: Ganshenyinxu; HYPERL: hyperlipidemia; HYPERT: hypertension; KA: absorption rate constant;
OFV: objective function value; PSYAX: Pishenyangxu; SCR: serum creatinine; SYAX: Shenyangxu; TCM: Traditional Chinese Medicine;
and V: central distribution volume.
Table 5 Control stream and OFV values of the forward covariate model of method two
Table 6 Control stream and OFV values of the backward covariate model of method two
Control stream
502full.ctl
502FULL.SYAX.ctl.
OFV
﹣1324.7020
﹣1312.5790
Model description
Full model
Remove SYAX
△OFV
-
14.324
P < 0.01 (OFV > 6.63)
-
Y
Notes: final model: 502full. ctl→ 502final.ctl. When OFV > 6.63 then P < 0.01. OFV: objective function value; N = no; Y = yes.
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Visual predictive checking of the NAR final model
with method two
The final model was checked by visual predictive
checking, and the results are shown in Figure 11.
Simulation of the NAR final model
To analyze the clinical impact of the statistically signifi-
cant covariates, concentration profiles were simulated
for a 250 mg single dose regimen, and the results are
shown in Figure 12.
DISCUSSION
PPK research is seldom carried out using TCM com-
pounds or formulas, mainly because of sensitivity limi-
tations. However, we used HPLC coupled with MS/
MS to detect the concentration of NAR in blood sam-
ples of patients after oral administration of one Qiang-
gu capsule. This study is important for PPK research
in TCM and will hopefully encourage further study
within the field. One advantage of PPK is that the in-
clusion and exclusion criteria are quite different from
those of classical pharmacokinetic studies. In fact, the
exclusion criteria of classical pharmacokinetic studies
are the inclusion criteria of PPK studies.
In addition to the usual covariates selected in PPK
studies, TCM symptoms and patterns can be consid-
ered as covariates and were added to our basic model
for the first time. The results indicate that adoption of
TCM patterns as covariates was necessary and mean-
ingful. Therefore, as long as the ingredients are proper-
ly selected, PPK in TCM is feasible and its results can
be implemented to assist in appropriate clinical utiliza-
tion and side effect reduction of corresponding drugs.
We also showed that the NONMEM approach can ef-
fectively estimate the distribution of parameters and
their relationships with covariates in a population and
provide a potential method of pharmacokinetic re-
search in TCM.
In recent years, various methods have been reported
for the quantification of NAR in biological samples us-
ing HPLC coupled with ultraviolet, fluorescence, or
mass spectrometry to support preclinical and clinical
studies.4-5 To fully evaluate the pharmacokinetics of
NAR in plasma, several sensitive HPLC-MS/MS assay
methods with appropriate sensitivity, selectivity, accu-
racy, and precision have been developed and validat-
ed.5-7 Although the pharmacokinetic characteristics of
purified NAR have been well investigated in animals,
few studies involving humans have been performed.
PPK can provide estimates of the sources and correla-
tions of variability in drug concentrations among in-
dividuals and analyze complex factors that may influ-
ence the pharmacokinetic behavior of a drug.8-14 How-
ever, PPK is seldom studied with TCM because the
function of a single ingredient cannot represent that of
the whole formula. Nevertheless, it can be concluded
from the results of this study that among a dozen co-
variates, only hyperlipidemia was significantly corre-
lated with NAR population parameters. NAR possess-
es a hypolipidemic effect, and could therefore have
potential for clinical applications. As long as the in-
gredients are properly selected, PPK studies using
TCM are not only feasible, but their results can be
implemented to assist in appropriate clinical utiliza-
tion and the side-effect reduction of corresponding
drugs.
Our population pharmacokinetic model effectively
characterized the pharmacokinetic profile of NAR after
administration of a single oral dose of Qianggu cap-
sules in Chinese women with primary osteoporosis.
Among the tested covariates, only SYAX, a pattern in
TCM, was a significant factor.
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Figure 10 Observed data versus predicted data of final of method two
A: the blue lines represent every possible opposite blood concentration point of the observations, the red lines represent the real
average plots, and the black lines indicate the fitness; B: two different visual forms of the 95% confidence line (plot form and line
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blood concentrations. Almost all the points were around the average line, which means that the weighted residuals are almost
the same; D: conditional weight residuals were around the zero line; E: the blue lines indicate every possible opposite blood con-
centration point of the observations, the red lines indicate the real average plots, and the black line indicates the fitness; F: the
normal distribution of the conditional weighted residuals means that the main diagnostic plots for the base model were reliable.
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Figure 11 Visual predictive checking of the final model with
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The top dotted line illustrates the 95th percentile of average
concentration. The solid line represents the mean concentra-
tion. The low dotted line illustrates the 5th percentile of av-
erage concentration.
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Figure 12 Concentration-time profiles predicated in popu-
lation in the Chinese women with primary osteoporosis
following a 250 mg single dose regimen with method two
The red dotted line (top) illustrates the SYAX 95th percen-
tile. The red solid line represents the SYAX mean. The red
dotted line (low) illustrates the SYAX 5th percentile. The
blue dotted line (top) illustrates the No SYAX 95th percen-
tile. The blue solid line represents the No SYAX mean. The
blue dotted line (low) illustrates the No SYAX 5th percen-
tile.
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